Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 9/20 | 0.43 |
| ▸ | TYR | P14679 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1188740 | 1.00 | ALOX5 (0.43) | ALOX5TYRCYP3A4MEN1TP53 | |
| SCHEMBL1187137 | 1.00 | ALOX5 (0.43) | ALOX5TYRCYP3A4MEN1TP53 | |
| SCHEMBL1186653 | 1.00 | ALOX5 (0.43) | ALOX5TYRCYP3A4MEN1TP53 | |
| SCHEMBL1187705 | 1.00 | ALOX5 (0.43) | ALOX5TYRCYP3A4MEN1TP53 | |
| SCHEMBL1187536 | 1.00 | ALOX5 (0.43) | ALOX5TYRCYP3A4MEN1TP53 | |
| SCHEMBL1187265 | 1.00 | ALOX5 (0.43) | ALOX5TYRCYP3A4MEN1TP53 | |
| SCHEMBL1186926 | 1.00 | ALOX5 (0.43) | ALOX5TYRCYP3A4MEN1TP53 | |
| SCHEMBL1186919 | 1.00 | ALOX5 (0.43) | ALOX5TYRCYP3A4MEN1TP53 | |
| SCHEMBL1186880 | 1.00 | ALOX5 (0.43) | ALOX5TYRCYP3A4MEN1TP53 | |
| SCHEMBL1187794 | 1.00 | ALOX5 (0.43) | ALOX5TYRCYP3A4MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481736-B2 | Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof | BASF SE (DE) | 2013-07-09 | — | — | US | disclosed |
| US-20110042651-A1 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110042651-A1 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | TPR, ROR1, CA3 | ALOX5 667/4885TYR 986/4885CYP3A4 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.